Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6395707B1 · kind B1 · utility
7Cited by
5References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 26, 1997 |
| Grant date | May 28, 2002 |
| Priority date | — |
| Expiry date | Jun 26, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are vascular endothelial cell growth factor (VEGF) variants having structural alterations in the C-terminus heparin binding domain and methods of use. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.